Ken Griffin X4 Pharmaceuticals, Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.86 $28,134 - $44,806	52,100 Added 212.65%	76,600 $51,000
Q2 2024 Aug 14, 2024	SELL	$0.58 - $1.47 $13,513 - $34,251	-23,300 Reduced 48.74%	24,500 $14,000
Q1 2024 May 15, 2024	BUY	$0.72 - $1.46 $24,696 - $50,078	34,300 Added 254.07%	47,800 $66,000
Q4 2023 Feb 14, 2024	SELL	$0.61 - $0.99 $29,036 - $47,124	-47,600 Reduced 77.91%	13,500 $11,000
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $155,427 - $304,818	-150,900 Reduced 71.18%	61,100 $66,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $142,434 - $432,513	173,700 Added 453.52%	212,000 $411,000
Q1 2023 May 15, 2023	SELL	$0.8 - $1.22 $5,600 - $8,540	-7,000 Reduced 15.45%	38,300 $33,000
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $13,454 - $43,095	19,500 Added 75.58%	45,300 $44,000
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.71 $979 - $1,881	1,100 Added 4.45%	25,800 $44,000

104

100M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.